Free public records show Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
8 active studies led by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., of 9 in all
Source: ClinicalTrials.gov, Studies with Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. is in.
Stories on the topics Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read
The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
ReadSearch all reports for Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. All companies